Abstract
The amyloid-β(Aβ ) cascade hypothesis of Alzheimers disease (AD) has dominated research and subsequent therapeutic drug development for over two decades. Central to this hypothesis is the observation that Aβ is elevated in AD patients and that the disease is ultimately characterized by the central deposition of insoluble senile plaques. More recent evidence, however, suggests that the presence or absence of plaque is insufficient to fully account for the deleterious role of elevated Aβ in AD. Such studies support the basis for an alternate interpretation of the Aβ cascade hypothesis. Namely, that soluble oligomers of Aβ (i.e., ADDLs) accumulate and cause functional deficits prior to overt neuronal cell death or plaque deposition. Accordingly, the following review focuses on research describing the preparation and functional activity of ADDLs in vitro and in vivo. These studies provide the basis for an alternate, ADDL-based, view of the Aβ cascade hypothesis and accounts for the disconnect between plaque burden and cognitive deficits. Possible therapeutic approaches aimed at lowering ADDLs in AD patients are also considered.
Keywords: NMDA antagonist, amyloid precursor protein, long-term potentiation (LTP), NSAID, glycosaminoglycans
Current Topics in Medicinal Chemistry
Title: The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimers Disease
Volume: 6 Issue: 6
Author(s): Susan M. Catalano, Elizabeth C. Dodson, Darrell A. Henze, Joseph G. Joyce, Grant A. Krafft and Gene G. Kinney
Affiliation:
Keywords: NMDA antagonist, amyloid precursor protein, long-term potentiation (LTP), NSAID, glycosaminoglycans
Abstract: The amyloid-β(Aβ ) cascade hypothesis of Alzheimers disease (AD) has dominated research and subsequent therapeutic drug development for over two decades. Central to this hypothesis is the observation that Aβ is elevated in AD patients and that the disease is ultimately characterized by the central deposition of insoluble senile plaques. More recent evidence, however, suggests that the presence or absence of plaque is insufficient to fully account for the deleterious role of elevated Aβ in AD. Such studies support the basis for an alternate interpretation of the Aβ cascade hypothesis. Namely, that soluble oligomers of Aβ (i.e., ADDLs) accumulate and cause functional deficits prior to overt neuronal cell death or plaque deposition. Accordingly, the following review focuses on research describing the preparation and functional activity of ADDLs in vitro and in vivo. These studies provide the basis for an alternate, ADDL-based, view of the Aβ cascade hypothesis and accounts for the disconnect between plaque burden and cognitive deficits. Possible therapeutic approaches aimed at lowering ADDLs in AD patients are also considered.
Export Options
About this article
Cite this article as:
Catalano M. Susan, Dodson C. Elizabeth, Henze A. Darrell, Joyce G. Joseph, Krafft A. Grant and Kinney G. Gene, The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimers Disease, Current Topics in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/156802606776743066
DOI https://dx.doi.org/10.2174/156802606776743066 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidant Status and Energy State of Erythrocytes in Alzheimer Dementia: Probing for Markers
CNS & Neurological Disorders - Drug Targets Markers of Atherosclerotic Disease: What do they Mean? Current Opinion and Future Trends
Current Pharmaceutical Design Brain Magnetic Stimulation in Animal Models: A Valuable Lesson for Clinical Applications
CNS & Neurological Disorders - Drug Targets Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Chronic Kidney Disease - Different Role for HDL?
Current Medicinal Chemistry Editorial (Thematic Issue: Cell Metabolism and Current Challenges in Drug Research)
Current Pharmaceutical Design Possible Physiopathological Roles of the Transglutaminase Activity in the Etiopathogenesis of Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Sleep Related Disorders in the Elderly: An Overview
Current Respiratory Medicine Reviews An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population
Current Neuropharmacology Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Biological Role of Formaldehyde, and Cycles Related to Methylation, Demethylation, and Formaldehyde Production
Mini-Reviews in Medicinal Chemistry Resurrecting Clinical Pharmacology As a Context for Alzheimer Disease Drug Development
Current Alzheimer Research Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease
Current Alzheimer Research The Role of Neuronal Insulin/Insulin-Like Growth Factor-1 Signaling for the Pathogenesis of Alzheimer’s Disease: Possible Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Role of COL4A1 in Basement-Membrane Integrity and Cerebral Small-Vessel Disease. The COL4A1 Stroke Syndrome
Current Medicinal Chemistry Alzheimer’s Disease Targeted Nano-Based Drug Delivery Systems
Current Drug Targets Chronic Psychosocial Stress Exacerbates Impairment of Synaptic Plasticity in β-Amyloid Rat Model of Alzheimers Disease: Prevention by Nicotine
Current Alzheimer Research Can Acetylcholinesterase Serve as a Target for Developing More Selective Insecticides?
Current Drug Targets